Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 6/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | FADS1 | O60427 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089269 | 0.85 | NPC1 (0.58) | EPHX1EPHX2GAANPC1RAB9A | |
| SCHEMBL5459120 | 0.83 | RORC (0.55) | EPHX1EPHX2NPC1RAB9AMEN1 | |
| SCHEMBL3461441 | 0.82 | KMT2A (0.67) | EPHX1EPHX2GAANPC1RAB9A | |
| SCHEMBL1092135 | 0.82 | EPHX1 (0.73) | EPHX1EPHX2GAANPC1RAB9A | |
| SCHEMBL11322912 | 0.81 | RAB9A (0.73) | NPC1RAB9AFADS1MEN1KMT2A | |
| SCHEMBL9137517 | 0.80 | GSTO1 (0.52) | NPC1RAB9AMAPTLMNAHTT | |
| SCHEMBL21698047 | 0.80 | CYP3A4 (0.51) | EPHX1EPHX2NPC1RAB9AFADS1 | |
| SCHEMBL8396885 | 0.80 | MEN1 (0.72) | NPC1RAB9AMEN1KMT2AMAPT | |
| Fluoride SCHEMBL11787935 | 0.80 | EPHX1 (0.70) | EPHX1EPHX2GAANPC1RAB9A | |
| Hydrochloric Acid SCHEMBL11153269 | 0.80 | EPHX1 (0.70) | EPHX1EPHX2GAANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DUKE UNIVERSITY (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | DUKE UNIVERSITY (US) | 2024-05-09 | — | — | US | disclosed |
| US-11801242-B2 | Compositions and methods for adjuvant cancer therapeutics | DUKE UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220008408-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | DUKE UNIVERSITY (US) | 2022-01-13 | — | — | US | disclosed |
| EP-3863633-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | Duke University (US) | 2021-08-18 | — | — | EP | disclosed |
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY | 2021-06-17 | — | — | US | disclosed |
| WO-2020028392-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DUKE UNIVERSITY (US) | 2020-02-06 | — | — | WO | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008408-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | TP53, PLK1, NRAS | EPHX1 2113/4885EPHX2 2077/4885GAA 1200/4885 |
| US-11801242-B2 | Compositions and methods for adjuvant cancer therapeutics | TP53, PLK1, NRAS | EPHX1 2113/4885EPHX2 2077/4885GAA 1200/4885 |
| US-20210179615-A1 | NICLOSAMIDE ANALOGUES AND THERAPEUTIC USE THEREOF | DNER, SFRP1, WNT1 | EPHX1 2998/4885EPHX2 3534/4885GAA 4114/4885 |
| US-11987579-B2 | Niclosamide analogues and therapeutic use thereof | DNER, SFRP1, WNT1 | EPHX1 2998/4885EPHX2 3534/4885GAA 4114/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | EPHX1 2224/4885EPHX2 3147/4885GAA 244/4885 |
| US-20240148716-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | TP53, PLK1, NRAS | EPHX1 2113/4885EPHX2 2077/4885GAA 1200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.